[In the media] Pill-Popping Is a Business Worth Watching for Japan’s Drugmakers (Bloomberg 2017, July 11)
date : 7/11/2017
HGPI’s Board Member Toshio Miyata’s commentary on pharmaceutical companies’ changing marketing strategies was featured in a Bloomberg article on Drugmakers in Japan. He pointed out that drug manufacturers are currently in a transitional period in which they are responding to changes in the medical system by diversifying their marketing strategies so that patients adhere to medication longer. He added that to achieve this end, manufacturers cannot keep on targeting sales to hospitals only, but rather should think together with different administrations and medical professionals on how to improve patients’ quality of life.
Top Research & Recommendations Posts
Featured Posts
-
2026-08-28
[Announcement] The 3rd Kiyoshi Kurokawa Award: Call for Nominations (Deadline: November 30, 2026)
-
2026-11-05
[Registration Open] HGPI Salon 2025-2026 Looking Ahead to the Future of Japan’s Social Security System “Session 7: Where We’ve Been and Where We’re Going: Lessons from Pandemic Response” (December 18, 2026)
-
2026-11-13
[Discussion Points] Addressing AMR Measures for an Era of Healthy Longevity: Ensuring Safety and Security for Older Adults in a Super-Aged Society (October 23, 2026)



